Bristol Myers Squibb (BMS) announced the expansion of its direct-to-patient initiatives to provide eligible U.S. patients with significant savings on select medicines. Through these programs, cash-paying patients will be able to purchase Eliquis (apixaban) and Sotyktu (deucravacitinib) directly from Bristol Myers Squibb at substantially reduced prices, lowering out-of-pocket costs and improving access.

Beginning in January 2026, Sotyktu, the company’s treatment for adults with moderate-to-severe plaque psoriasis, will be offered through BMS Patient Connect, a new direct-to-patient platform. Eligible patients will have access to Sotyktu at more than 80 per cent below the current list price, with delivery available across all 50 U.S. states and Puerto Rico.

This expansion builds on the Bristol Myers Squibb-Pfizer Alliance direct-to-patient program for Eliquis, launched earlier this month, which offers the medicine at more than 40 per cent below the current list price.

“We are committed to making our innovative therapies more accessible and affordable for patients living with serious conditions,” said Christopher Boerner, Ph.D., Board Chair and Chief Executive Officer, Bristol Myers Squibb. “With the launch of BMS Patient Connect and the inclusion of Sotyktu, we are removing barriers, enhancing transparency, and reducing costs so that patients across the United States can more easily obtain the treatments they need.”

BMS Patient Connect will provide a simplified purchasing option for eligible patients with prescriptions, offering clear visibility into costs, convenient nationwide delivery, and access to patient support resources. The platform is designed to expand over time to include additional Bristol Myers Squibb medicines where appropriate.